Xueyu Mao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xueyu Mao has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Huicong Niu
Fudan University
7 shared publications - Jing Zhao
Department of Neurology Minhang Hospital, Fudan University Shanghai China
7 shared publications Min Chu
Fudan University
6 shared publicationsLulu Sun
Suzhou Medical College of Soochow University
5 shared publicationsMengyao Shi
Suzhou Medical College of Soochow University
5 shared publicationsXuechun Wu
Fudan University
5 shared publications
Latest Publications
- Open Access
- 21 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (14) , e046952
Plasma Apolipoprotein E Levels and Adverse Clinical Outcomes After Ischemic Stroke
Background: Apolipoprotein E (ApoE) is implicated in the development of cerebrovascular diseases, but its association with the prognosis of ischemic stroke remains unclear. We aimed to explore the associations between plasma ApoE levels and adverse clinical outcomes after ischemic stroke in a prognostic cohort study. Method: We measured plasma ApoE levels among 5410 patients with ischemic stroke from the Minhang Stroke Cohort study. The primary outcome was the composite outcome of death and major disability (modified Rankin Scale score=3–6) at 3 months after stroke onset. Secondary outcomes included major disability, death, and the ordered 7‐level categorical score of the modified Rankin Scale. Results: In the prognostic cohort study, the multivariable adjusted odds ratio associated with the highest quartile of plasma ApoE levels was 1.37 (95% CI=1.10–1.70; P trend =0.003) for the primary outcome, 1.50 (95% CI=1.08–2.09; P trend =0.019) for death, and 1.47 (95% CI=1.11–1.95; P trend =0.005) for major disability. There was a worse shift in the distribution of modified Rankin Scale score at 3 months with higher quartiles of plasma ApoE levels among patients with ischemic stroke ( P trend =0.034). The multivariable‐adjusted spline regression model further showed positive linear associations of plasma ApoE levels with the primary outcome, death, and major disability (all P for linearity<0.05). Conclusions: High plasma ApoE levels were independently associated with increased risk of adverse outcomes among patients with ischemic stroke, suggesting that plasma ApoE might be implicated in the prognosis of ischemic stroke.
- 21 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (14) , e046952
Open AccessPlasma Apolipoprotein E Levels and Adverse Clinical Outcomes After Ischemic Stroke
Background: Apolipoprotein E (ApoE) is implicated in the development of cerebrovascular diseases, but its association with the prognosis of ischemic stroke remains unclear. We aimed to explore the associations between plasma ApoE levels and adverse clinical outcomes after ischemic stroke in a prognostic cohort study. Method: We measured plasma ApoE levels among 5410 patients with ischemic stroke from the Minhang Stroke Cohort study. The primary outcome was the composite outcome of death and major disability (modified Rankin Scale score=3–6) at 3 months after stroke onset. Secondary outcomes included major disability, death, and the ordered 7‐level categorical score of the modified Rankin Scale. Results: In the prognostic cohort study, the multivariable adjusted odds ratio associated with the highest quartile of plasma ApoE levels was 1.37 (95% CI=1.10–1.70; P trend =0.003) for the primary outcome, 1.50 (95% CI=1.08–2.09; P trend =0.019) for death, and 1.47 (95% CI=1.11–1.95; P trend =0.005) for major disability. There was a worse shift in the distribution of modified Rankin Scale score at 3 months with higher quartiles of plasma ApoE levels among patients with ischemic stroke ( P trend =0.034). The multivariable‐adjusted spline regression model further showed positive linear associations of plasma ApoE levels with the primary outcome, death, and major disability (all P for linearity<0.05). Conclusions: High plasma ApoE levels were independently associated with increased risk of adverse outcomes among patients with ischemic stroke, suggesting that plasma ApoE might be implicated in the prognosis of ischemic stroke.
- Open Access
- 20 January 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (2) , e046136
Associations of Serum Complement Biomarkers With Adverse Clinical Outcomes Among Patients With Ischemic Stroke
Background: The complement system plays a crucial role in immune regulation and inflammatory response and is believed to be involved in the onset and progression of ischemic stroke. Therefore, we aimed to investigate the associations of baseline serum complement C3 and C4 levels with the prognosis of ischemic stroke. Methods: We measured baseline serum complemental C3 and C4 levels in 3979 patients with ischemic stroke from the Minhang Stroke Cohort. The primary outcome was death or major disability at discharge after ischemic stroke. Secondary outcomes included major disability, death, and pneumonia. In addition, we constructed a complement biomarker score based on serum complement C3 and C4 levels to systematically evaluate the impact of the complement system on the prognosis among patients with ischemic stroke. Results: Among the 3979 patients with ischemic stroke, 1360 (34.18%) experienced death or major disability at discharge. After multivariable adjustment, the odds ratios of the primary outcome for the highest versus the lowest quartile were 1.34 (95% confidence intervals [CI], 1.06–1.69; P trend =0.013) for complement C3, 1.34 (95% CI, 1.06–1.69; P trend =0.014) for complement C4, and 1.32 (95% CI, 1.05–1.67; P trend =0.018) for the complement biomarker score. Multivariable‐adjusted restricted cubic spline analyses indicated linear dose–response relationships of serum complement C3 ( P linearity =0.025), complement C4 ( P linearity =0.021), and complement biomarker score ( P linearity =0.011) with the risk of primary outcome. Adding the complement biomarker score to conventional models resulted in significant improvement in risk discrimination for the poor outcomes after ischemic stroke, as evidenced by integrated discrimination improvement (all P <0.05). Conclusions: High serum complement C3 and C4 levels were associated with increased risks of adverse outcomes at discharge after ischemic stroke, suggesting that the complement system might be implicated in the progression of ischemic stroke and could be potential intervention targets for improving prognosis.
- 20 January 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (2) , e046136
Open AccessAssociations of Serum Complement Biomarkers With Adverse Clinical Outcomes Among Patients With Ischemic Stroke
Background: The complement system plays a crucial role in immune regulation and inflammatory response and is believed to be involved in the onset and progression of ischemic stroke. Therefore, we aimed to investigate the associations of baseline serum complement C3 and C4 levels with the prognosis of ischemic stroke. Methods: We measured baseline serum complemental C3 and C4 levels in 3979 patients with ischemic stroke from the Minhang Stroke Cohort. The primary outcome was death or major disability at discharge after ischemic stroke. Secondary outcomes included major disability, death, and pneumonia. In addition, we constructed a complement biomarker score based on serum complement C3 and C4 levels to systematically evaluate the impact of the complement system on the prognosis among patients with ischemic stroke. Results: Among the 3979 patients with ischemic stroke, 1360 (34.18%) experienced death or major disability at discharge. After multivariable adjustment, the odds ratios of the primary outcome for the highest versus the lowest quartile were 1.34 (95% confidence intervals [CI], 1.06–1.69; P trend =0.013) for complement C3, 1.34 (95% CI, 1.06–1.69; P trend =0.014) for complement C4, and 1.32 (95% CI, 1.05–1.67; P trend =0.018) for the complement biomarker score. Multivariable‐adjusted restricted cubic spline analyses indicated linear dose–response relationships of serum complement C3 ( P linearity =0.025), complement C4 ( P linearity =0.021), and complement biomarker score ( P linearity =0.011) with the risk of primary outcome. Adding the complement biomarker score to conventional models resulted in significant improvement in risk discrimination for the poor outcomes after ischemic stroke, as evidenced by integrated discrimination improvement (all P <0.05). Conclusions: High serum complement C3 and C4 levels were associated with increased risks of adverse outcomes at discharge after ischemic stroke, suggesting that the complement system might be implicated in the progression of ischemic stroke and could be potential intervention targets for improving prognosis.
- Open Access
- 20 May 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (10) , e037601
High‐Normal Serum Potassium, Calcium, and Magnesium Levels Are Associated With Decreased Risks of Adverse Outcomes After Ischemic Stroke
Background: High serum potassium, calcium, and magnesium levels have been reported to be associated with decreased risks of ischemic stroke, whereas their prognostic values in ischemic stroke remain unclear. We aimed to prospectively explore the associations of serum potassium, calcium, and magnesium levels with the prognosis of ischemic stroke. Methods: We measured serum potassium, calcium, and magnesium levels at baseline among 5469 patients with ischemic stroke from the Minhang Stroke Cohort study. The primary outcome was the composite outcome of death and major disability (modified Rankin Scale score ≥3) at 3 months after ischemic stroke. Secondary outcomes included major disability, death, and the ordered 7‐level categorical score of the modified Rankin Scale. Results: During 3‐month follow‐up, 1834 patients developed the primary outcome. After multivariate adjustment, the adjusted odds ratios of primary outcome for the highest versus the lowest quartile were 0.79 (95% CI, 0.68–0.93; P trend =0.007) for potassium, 0.69 (95% CI, 0.58–0.82; P trend P trend =0.015) for magnesium. Multivariable‐adjusted restricted cubic spline analyses showed linear dose–response relationships of serum potassium, calcium, and magnesium with the risk of primary outcome (all P for linearity<0.05). Conclusions: High‐normal serum potassium, calcium, and magnesium levels were associated with decreased risks of adverse outcomes at 3 months after ischemic stroke, suggesting that serum potassium, calcium, and magnesium might be valuable prognostic biomarkers for ischemic stroke.
- 20 May 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (10) , e037601
Open AccessHigh‐Normal Serum Potassium, Calcium, and Magnesium Levels Are Associated With Decreased Risks of Adverse Outcomes After Ischemic Stroke
Background: High serum potassium, calcium, and magnesium levels have been reported to be associated with decreased risks of ischemic stroke, whereas their prognostic values in ischemic stroke remain unclear. We aimed to prospectively explore the associations of serum potassium, calcium, and magnesium levels with the prognosis of ischemic stroke. Methods: We measured serum potassium, calcium, and magnesium levels at baseline among 5469 patients with ischemic stroke from the Minhang Stroke Cohort study. The primary outcome was the composite outcome of death and major disability (modified Rankin Scale score ≥3) at 3 months after ischemic stroke. Secondary outcomes included major disability, death, and the ordered 7‐level categorical score of the modified Rankin Scale. Results: During 3‐month follow‐up, 1834 patients developed the primary outcome. After multivariate adjustment, the adjusted odds ratios of primary outcome for the highest versus the lowest quartile were 0.79 (95% CI, 0.68–0.93; P trend =0.007) for potassium, 0.69 (95% CI, 0.58–0.82; P trend P trend =0.015) for magnesium. Multivariable‐adjusted restricted cubic spline analyses showed linear dose–response relationships of serum potassium, calcium, and magnesium with the risk of primary outcome (all P for linearity<0.05). Conclusions: High‐normal serum potassium, calcium, and magnesium levels were associated with decreased risks of adverse outcomes at 3 months after ischemic stroke, suggesting that serum potassium, calcium, and magnesium might be valuable prognostic biomarkers for ischemic stroke.
- Open Access
- 6 May 2025
- Published by Wolters Kluwer Health in Stroke
Elevated Remnant Cholesterol Improves the Prognosis of Patients With Ischemic Stroke and Malnutrition: A Cohort-Based Study
BACKGROUND: The mechanism of the lipid paradox remains uncertain, and malnutrition may be 1 explanation. In this prospective cohort study, we explored the associations between baseline remnant cholesterol (RC) concentrations and clinical outcomes in patients with ischemic stroke, stratified by nutritional status. METHODS: Patients with ischemic stroke in a single-center prospective cohort (Shanghai, China) from January 2018 to December 2022 were studied. Individuals were classified into 3 groups based on their Controlling Nutritional Status score. Poor outcome and all-cause mortality during up to 3 months of follow-up were compared among patients with varied nutritional status and RC levels utilizing multivariate logistic regression analyses, RC splines, and subgroup analyses. RESULTS: A total of 6892 patients with ischemic stroke were enrolled in the cohort, of which 5257 patients were included in the present study (without malnutrition: 2418 [46.0%]; mild malnutrition: 2516 [47.9%]; moderate-severe malnutrition: 323 [6.1%]). The median age was 69±12 years, and 3398 (64.6%) were male. Patients with moderate-severe malnutrition had the highest risks of poor outcome (198 [61.3%]; P P P <0.05), which was not observed in patients without malnutrition. In addition, compared with the moderate-severely malnourished with RC <0.471 mmol/L, the adjusted odds ratios for poor outcome and all-cause mortality were 0.805 (95% CI, 0.450–1.438) and 0.898 (0.502–1.607) for participants with 0.471 to 0.632 mmol/L, 0.259 (0.095–0.704) and 0.222 (0.061–0.810) for 0.633 to 0.868 mmol/L, and 0.160 (0.037–0.689) and 0.202 (0.042–0.967) for ≥0.869 mmol/L, respectively. CONCLUSIONS: The lipid paradox was only observed in the malnourished patients with ischemic stroke. Strict lipid reduction therapy is still recommended for patients without malnutrition. However, when treating patients at any risk of malnutrition, the improvement of nutritional status may be more crucial.
- 6 May 2025
- Published by Wolters Kluwer Health in Stroke
Open AccessElevated Remnant Cholesterol Improves the Prognosis of Patients With Ischemic Stroke and Malnutrition: A Cohort-Based Study
BACKGROUND: The mechanism of the lipid paradox remains uncertain, and malnutrition may be 1 explanation. In this prospective cohort study, we explored the associations between baseline remnant cholesterol (RC) concentrations and clinical outcomes in patients with ischemic stroke, stratified by nutritional status. METHODS: Patients with ischemic stroke in a single-center prospective cohort (Shanghai, China) from January 2018 to December 2022 were studied. Individuals were classified into 3 groups based on their Controlling Nutritional Status score. Poor outcome and all-cause mortality during up to 3 months of follow-up were compared among patients with varied nutritional status and RC levels utilizing multivariate logistic regression analyses, RC splines, and subgroup analyses. RESULTS: A total of 6892 patients with ischemic stroke were enrolled in the cohort, of which 5257 patients were included in the present study (without malnutrition: 2418 [46.0%]; mild malnutrition: 2516 [47.9%]; moderate-severe malnutrition: 323 [6.1%]). The median age was 69±12 years, and 3398 (64.6%) were male. Patients with moderate-severe malnutrition had the highest risks of poor outcome (198 [61.3%]; P P P <0.05), which was not observed in patients without malnutrition. In addition, compared with the moderate-severely malnourished with RC <0.471 mmol/L, the adjusted odds ratios for poor outcome and all-cause mortality were 0.805 (95% CI, 0.450–1.438) and 0.898 (0.502–1.607) for participants with 0.471 to 0.632 mmol/L, 0.259 (0.095–0.704) and 0.222 (0.061–0.810) for 0.633 to 0.868 mmol/L, and 0.160 (0.037–0.689) and 0.202 (0.042–0.967) for ≥0.869 mmol/L, respectively. CONCLUSIONS: The lipid paradox was only observed in the malnourished patients with ischemic stroke. Strict lipid reduction therapy is still recommended for patients without malnutrition. However, when treating patients at any risk of malnutrition, the improvement of nutritional status may be more crucial.
- 1 January 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (1) , e1-e2
Neuron-Specific Enolase Levels and Prognosis of Ischemic Stroke: Two Prospective Cohort Studies
- 1 January 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (1) , e1-e2
Neuron-Specific Enolase Levels and Prognosis of Ischemic Stroke: Two Prospective Cohort Studies
- Open Access
- 1 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (19) , e036527
Folate, Homocysteine, and Adverse Outcomes After Ischemic Stroke
Background: As a risk factor of cardiovascular diseases, homocysteine can be effectively lowered by folate. However, the associations of folate and homocysteine levels with the prognosis of ischemic stroke remained unclear. Methods and Results: A total of 3530 patients with ischemic stroke were included. Serum folate and homocysteine levels were measured at admission. The primary outcome was composite of death and major disability (modified Rankin Scale score≥3) at 3 months after stroke onset. Univariate and multivariate logistic regression models were used. The mediation effect of homocysteine was examined. During follow‐up, 1056 participants developed the primary outcome. In the univariate model, participants in the highest quartile of folate had a 29% (95% CI, 0.58–0.87) decreased risk of primary outcome compared with those in the lowest quartile. After multivariate adjustment, the odds ratio associated with the highest quartile of folate was 0.58 (95% CI, 0.46–0.73) for primary outcome. In contrast, participants in the highest quartile of homocysteine had a 52% (95% CI, 1.24–1.98) increased risk of primary outcome compared with those in the lowest quartile. After multivariate adjustment, the odds ratio associated with highest quartile of homocysteine was 1.57 (95% CI, 1.24–1.98) for primary outcome. In addition, 25.5% of the observed associations between folate and primary outcome was mediated through homocysteine ( P =0.012). Conclusions: High folate levels were associated with low risks of death and major disability among Chinese patients with ischemic stroke, and homocysteine partially mediated the observed potential beneficial role of folate.
- 1 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (19) , e036527
Open AccessFolate, Homocysteine, and Adverse Outcomes After Ischemic Stroke
Background: As a risk factor of cardiovascular diseases, homocysteine can be effectively lowered by folate. However, the associations of folate and homocysteine levels with the prognosis of ischemic stroke remained unclear. Methods and Results: A total of 3530 patients with ischemic stroke were included. Serum folate and homocysteine levels were measured at admission. The primary outcome was composite of death and major disability (modified Rankin Scale score≥3) at 3 months after stroke onset. Univariate and multivariate logistic regression models were used. The mediation effect of homocysteine was examined. During follow‐up, 1056 participants developed the primary outcome. In the univariate model, participants in the highest quartile of folate had a 29% (95% CI, 0.58–0.87) decreased risk of primary outcome compared with those in the lowest quartile. After multivariate adjustment, the odds ratio associated with the highest quartile of folate was 0.58 (95% CI, 0.46–0.73) for primary outcome. In contrast, participants in the highest quartile of homocysteine had a 52% (95% CI, 1.24–1.98) increased risk of primary outcome compared with those in the lowest quartile. After multivariate adjustment, the odds ratio associated with highest quartile of homocysteine was 1.57 (95% CI, 1.24–1.98) for primary outcome. In addition, 25.5% of the observed associations between folate and primary outcome was mediated through homocysteine ( P =0.012). Conclusions: High folate levels were associated with low risks of death and major disability among Chinese patients with ischemic stroke, and homocysteine partially mediated the observed potential beneficial role of folate.
- Open Access
Elevated remnant cholesterol improves prognosis of patients with ischemic stroke and malnutrition: a cohort-based study
Background: Aggressive lipid-lowering therapy is recommended for patients with ischemic stroke; however, lipid paradox has been reported in several clinical studies. The mechanism of lipid paradox remains uncertain, and nutrition maybe one explanation. In this prospective cohort study, we explored the associations between baseline remnant cholesterol (RC) concentrations and clinical outcomes in patients with ischemic stroke, stratified by nutritional status. Materials and Methods: A total of 5257 patients with ischemic stroke were recruited for analysis. The Controlling Nutritional Status (CONUT) score was utilized to investigate the risk of malnutrition. Individuals were classified into 4 groups based on their CONUT score. Poor outcomes and all-cause mortality were compared among patients with varied nutritional status and RC levels. Results: Patients with moderate-severe malnutrition had the highest incidences of in-hospital complications, including pulmonary infection, renal dysfunction, and hemorrhagic transformation, and the highest rates of poor outcomes (61.3%, P P < 0.001) during the 3-month follow-up period. Baseline higher RC level was an independent protective factor of adverse clinical outcomes for patients with any degree of malnutrition, which was not observed in patients without malnutrition. In addition, compared with the moderate-severe malnourished with RC <0.471 mmol/L, the adjusted ORs for poor outcomes and all-cause mortality were 0.805 (0.450–1.438) and 0.898 (0.502-1.607) for participants with 0.471-0.632 mmol/L, 0.259 (0.095-0.704) and 0.222 (0.061-0.810) for 0.633-0.868 mmol/L, and 0.160 (0.037–0.689) and 0.202 (0.042-0.967) for ≥ 0.869 mmol/L, prospectively. Conclusion: Lipid paradox was only observed in the malnourished patients with ischemic stroke. Strict lipid reduction therapy is still recommended for patients with ischemic stroke and good nutritional status. However, when treating patients at any risk of malnutrition, the improvement of nutritional status may be more crucial than aggressive lipid control.
Open AccessElevated remnant cholesterol improves prognosis of patients with ischemic stroke and malnutrition: a cohort-based study
Background: Aggressive lipid-lowering therapy is recommended for patients with ischemic stroke; however, lipid paradox has been reported in several clinical studies. The mechanism of lipid paradox remains uncertain, and nutrition maybe one explanation. In this prospective cohort study, we explored the associations between baseline remnant cholesterol (RC) concentrations and clinical outcomes in patients with ischemic stroke, stratified by nutritional status. Materials and Methods: A total of 5257 patients with ischemic stroke were recruited for analysis. The Controlling Nutritional Status (CONUT) score was utilized to investigate the risk of malnutrition. Individuals were classified into 4 groups based on their CONUT score. Poor outcomes and all-cause mortality were compared among patients with varied nutritional status and RC levels. Results: Patients with moderate-severe malnutrition had the highest incidences of in-hospital complications, including pulmonary infection, renal dysfunction, and hemorrhagic transformation, and the highest rates of poor outcomes (61.3%, P P < 0.001) during the 3-month follow-up period. Baseline higher RC level was an independent protective factor of adverse clinical outcomes for patients with any degree of malnutrition, which was not observed in patients without malnutrition. In addition, compared with the moderate-severe malnourished with RC <0.471 mmol/L, the adjusted ORs for poor outcomes and all-cause mortality were 0.805 (0.450–1.438) and 0.898 (0.502-1.607) for participants with 0.471-0.632 mmol/L, 0.259 (0.095-0.704) and 0.222 (0.061-0.810) for 0.633-0.868 mmol/L, and 0.160 (0.037–0.689) and 0.202 (0.042-0.967) for ≥ 0.869 mmol/L, prospectively. Conclusion: Lipid paradox was only observed in the malnourished patients with ischemic stroke. Strict lipid reduction therapy is still recommended for patients with ischemic stroke and good nutritional status. However, when treating patients at any risk of malnutrition, the improvement of nutritional status may be more crucial than aggressive lipid control.
- Open Access
- 11 May 2022
- Published by MDPI AG in Brain Sciences
- Vol. 12 (5) , 631
Preconditioned MSCs Alleviate Cerebral Ischemia-Reperfusion Injury in Rats by Improving the Neurological Function and the Inhibition of Apoptosis
Mesenchymal stem cells (MSCs) have great application prospects in the treatment of ischemic injury. However, their long-time cultivation before transplantation and poor survival after transplantation greatly limit the therapeutic effect and applications. This study aimed to investigate whether MSCs under the ischemic microenvironment could improve their survival and better alleviate cerebral ischemic injury. Firstly, we used ischemic brain tissue to culture MSCs and evaluated the functional changes of MSCs. Then a middle cerebral artery occlusion (MCAO) model was induced in rats, and the pretreated MSCs were injected via the tail vein. The adhesive removal test, rotarod test, modified neurological severity score, and pathological analyses were applied to assess the rats’ neurological function. Then the expression of neuron and apoptosis related markers was detected. The results indicated that ischemic brain tissue pretreated MSCs promoted the proliferation and the release of the growth factors of MSCs. Meanwhile, in MCAO model rats, transplantation of pretreated MSCs enhanced the neurogenesis, attenuated behavioral changes, reduced infarct size, and inhibited apoptosis. The expression of B-cell lymphoma-2 (Bcl-2), brain-derived neurotrophic factor (BDNF), glial fibrillary acidic protein (GFAP), NF-L, and NeuN were increased, while BCL2-Associated X (Bax) and Caspase-3 decreased. Our results suggest that MSCs pretreatment with stroke brain tissue could be an effective strategy in treating cerebral ischemic injury.
- 11 May 2022
- Published by MDPI AG in Brain Sciences
- Vol. 12 (5) , 631
Open AccessPreconditioned MSCs Alleviate Cerebral Ischemia-Reperfusion Injury in Rats by Improving the Neurological Function and the Inhibition of Apoptosis
Mesenchymal stem cells (MSCs) have great application prospects in the treatment of ischemic injury. However, their long-time cultivation before transplantation and poor survival after transplantation greatly limit the therapeutic effect and applications. This study aimed to investigate whether MSCs under the ischemic microenvironment could improve their survival and better alleviate cerebral ischemic injury. Firstly, we used ischemic brain tissue to culture MSCs and evaluated the functional changes of MSCs. Then a middle cerebral artery occlusion (MCAO) model was induced in rats, and the pretreated MSCs were injected via the tail vein. The adhesive removal test, rotarod test, modified neurological severity score, and pathological analyses were applied to assess the rats’ neurological function. Then the expression of neuron and apoptosis related markers was detected. The results indicated that ischemic brain tissue pretreated MSCs promoted the proliferation and the release of the growth factors of MSCs. Meanwhile, in MCAO model rats, transplantation of pretreated MSCs enhanced the neurogenesis, attenuated behavioral changes, reduced infarct size, and inhibited apoptosis. The expression of B-cell lymphoma-2 (Bcl-2), brain-derived neurotrophic factor (BDNF), glial fibrillary acidic protein (GFAP), NF-L, and NeuN were increased, while BCL2-Associated X (Bax) and Caspase-3 decreased. Our results suggest that MSCs pretreatment with stroke brain tissue could be an effective strategy in treating cerebral ischemic injury.